<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Frontotemporal dementia: Treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Frontotemporal dementia: Treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Frontotemporal dementia: Treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Suzee E Lee, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven T DeKosky, MD, FAAN, FACP, FANA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet L Wilterdink, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 04, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H9729241">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Frontotemporal dementia (FTD) is a neuropathologically and clinically heterogeneous disorder characterized by focal degeneration of the frontal and/or temporal lobes [
         <a href="#rid1">
          1
         </a>
         ]. Age of onset is typically in the late 50s or early 60s. The primary initial clinical manifestations include changes in personality and social behavior or language, progressing over time to a more global dementia affecting other cognitive domains. A subset of patients may also exhibit symptoms of extrapyramidal or motor neuron involvement during the disease course.
        </p>
        <p>
         There are no current US Food and Drug Administration (FDA)-approved disease-modifying treatments for FTD. Since the underlying pathology of FTD usually consists of tau or TAR DNA binding protein (TDP-43) aggregates, treatments geared toward beta-amyloid reduction that appear promising in Alzheimer disease (AD) are not expected to be effective for FTD.
        </p>
        <p>
         Symptomatic relief can be provided by a variety of agents. However, these medications are not FDA approved for FTD and have limited evidence of efficacy. These medications should be considered in conjunction with nonpharmacologic interventions, such as thoughtful evaluation of the patient's living environment.
        </p>
        <p>
         This topic discusses treatment issues specific to patients with FTD. Epidemiology, pathology, clinical features, and diagnosis of FTD, and the management of other forms of dementia, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14138.html" rel="external">
          "Frontotemporal dementia: Epidemiology, pathology, and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5070.html" rel="external">
          "Frontotemporal dementia: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5073.html" rel="external">
          "Treatment of Alzheimer disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5086.html" rel="external">
          "Treatment of vascular cognitive impairment and dementia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5092.html" rel="external">
          "Prognosis and treatment of dementia with Lewy bodies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5080.html" rel="external">
          "Management of the patient with dementia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3082241763">
         <span class="h1">
          NONPHARMACOLOGIC INTERVENTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to managing behavior, nonpharmacologic interventions focus on health maintenance and safety. Nonpharmacologic treatment requires a strong partnership with the patient's caregivers.
        </p>
        <p class="headingAnchor" id="H1191806427">
         <span class="h2">
          Safety and driving
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of prominent behavioral changes and impulsivity, safety becomes a concern early on in FTD. Patients often need protection from serious consequences of impaired judgment; supervision of financial decision-making, early retirement, and driving safety should be assessed and discussed in initial office visits [
         <a href="#rid2">
          2-4
         </a>
         ]. A practice parameter published by the American Academy of Neurology provides guidelines regarding driving safety and discontinuation of driving [
         <a href="#rid5">
          5
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3005.html" rel="external">
          "Approach to the evaluation of older drivers", section on 'Cognitive function'
         </a>
         ). Physical supervision may be required if patients demonstrate behavior that is dangerous to themselves or others. These issues are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5080.html" rel="external">
          "Management of the patient with dementia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3372093749">
         <span class="h2">
          Exercise and mobility
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regular cardiovascular exercise should be encouraged for both general health and also the enhancement of cognition in patients with dementia. Exercise programs have demonstrated benefits in both mood and cognition in patients with dementia, and their importance should not be underestimated. (See
         <a class="medical medical_review" href="/z/d/html/5080.html" rel="external">
          "Management of the patient with dementia", section on 'Exercise programs'
         </a>
         .)
        </p>
        <p>
         Mobility becomes a problem in patients with FTD later in the disease course, particularly for those with prominent parkinsonism or amyotrophic lateral sclerosis (ALS). Physical therapy can help with balance and help maintain physical activity [
         <a href="#rid6">
          6
         </a>
         ]. Physical aids such as a raised toilet seat, commodes, and removal of unsecured rugs can help reduce the potential for injuries in the home [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1352064491">
         <span class="h2">
          Speech therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Speech therapy and the use of communication aids may provide benefit early on in patients with semantic variant or nonfluent variant primary progressive aphasia [
         <a href="#rid6">
          6
         </a>
         ]. Later in the course of the illness, evaluation of swallowing is critical to prevent aspiration.
        </p>
        <p class="headingAnchor" id="H3403704523">
         <span class="h2">
          Behavioral modification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonpharmacologic behavioral modification techniques can be a useful adjunct in the management of the problematic behaviors in FTD. A behavioral monitoring log may help identify triggers that can be avoided or otherwise managed [
         <a href="#rid7">
          7
         </a>
         ]. Distraction, redirection, and offering of simple choices can be effective alternatives to medications for disinhibition, compulsive habits or rituals, agitation, and anxiety, but require caregiver education and support [
         <a href="#rid8">
          8
         </a>
         ]. A structured environment that avoids overstimulation can provide stability and predictability for the patient. Providing environmental cues for behaviors that should be encouraged (eg, laying out clothing, tools for self-care) and removing environmental cues for behaviors that should be discouraged (eg, car keys) can also be useful in some patients.
        </p>
        <p>
         Caregiver stress is a significant problem in FTD. Respite care and support groups are available in most areas, often through the local agency on aging [
         <a href="#rid4">
          4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Support for caregivers'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9729248">
         <span class="h1">
          PHARMACOLOGIC TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacologic treatment in FTD is symptomatic and aimed at alleviating neurobehavioral symptoms. Despite the fact that medications are commonly used for behavior symptoms, there is limited evidence regarding the efficacy of pharmacologic treatments in FTD [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9729255">
         <span class="h2">
          Neurotransmitter systems
         </span>
         <span class="headingEndMark">
          —
         </span>
         A neurochemical basis for FTD remains to be fully elucidated. Nonetheless, studies have indicated problems in certain neurotransmitter systems:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abnormalities in serotonin activity have been demonstrated in autopsy, neuroimaging, and cerebrospinal fluid studies in patients with FTD [
         <a href="#rid10">
          10,11
         </a>
         ]. In addition, serotonergic dysfunction has been linked to many of the behavioral problems that are common in FTD. However, these associations have been made, for the most part, in patients without rather than those with FTD [
         <a href="#rid2">
          2,12-15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dopaminergic function can also be altered in patients with FTD, usually in proportion to the severity of extrapyramidal motor symptoms [
         <a href="#rid16">
          16,17
         </a>
         ]. One study found that increased activity of dopaminergic neurotransmission and altered serotonergic modulation of dopaminergic neurotransmission were specifically associated with agitated and aggressive behavior, respectively [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The cholinergic system appears to be relatively preserved in FTD, in contrast to Alzheimer disease (AD) [
         <a href="#rid10">
          10,11,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3621313235">
         <span class="h2">
          Cognitive dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         No medications have been demonstrated to improve or stabilize cognitive deficits in patients with FTD.
        </p>
        <p>
         The available data do not support the use of cholinesterase inhibitors in FTD. The primary exception is when there is uncertainty about whether the patient has FTD or AD. In such cases, a therapeutic trial of a cholinesterase inhibitor is reasonable, given data supporting modest symptomatic benefits in patients with AD. (See
         <a class="medical medical_review" href="/z/d/html/5072.html" rel="external">
          "Cholinesterase inhibitors in the treatment of dementia", section on 'Indications'
         </a>
         .)
        </p>
        <p>
         One placebo-controlled eight-week trial of
         <a class="drug drug_general" data-topicid="8739" href="/z/d/drug information/8739.html" rel="external">
          galantamine
         </a>
         in patients with FTD suggested a trend toward benefit in the subgroup of patients with primary progressive aphasia, but not in patients with behavioral variant FTD (bvFTD) [
         <a href="#rid19">
          19
         </a>
         ]. An open-label study of
         <a class="drug drug_general" data-topicid="9529" href="/z/d/drug information/9529.html" rel="external">
          rivastigmine
         </a>
         found a benefit of treatment on measures of executive function but not global cognition as measured by the Mini-Mental State Examination [
         <a href="#rid20">
          20
         </a>
         ]. Finally, an open-label study of
         <a class="drug drug_general" data-topicid="9383" href="/z/d/drug information/9383.html" rel="external">
          donepezil
         </a>
         found no benefit of treatment on cognitive measure; some patients developed worsened behaviors [
         <a href="#rid21">
          21
         </a>
         ]. More recent studies have replicated these findings and have also found that discontinuation of donepezil sometimes resulted in improved behavior symptoms [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9729262">
         <span class="h2">
          Behavioral changes
         </span>
        </p>
        <p class="headingAnchor" id="H9729270">
         <span class="h3">
          Considerations prior to treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Behavioral symptoms can be variable and include socially inappropriate behavior, apathy and inertia, agitation, and compulsions that manifest as hoarding or abnormal eating behaviors. These are described in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5070.html" rel="external">
          "Frontotemporal dementia: Clinical features and diagnosis", section on 'Behavioral variant FTD'
         </a>
         .)
        </p>
        <p>
         Behavioral symptoms arise early in bvFTD and may also be problematic in the other subtypes of FTD (semantic and nonfluent primary progressive aphasia). These symptoms contribute substantively to the care burden of patients with FTD and can be challenging to treat [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         When neurobehavioral problems appear or worsen, clinicians should consider the possibility of delirium, pain, or discomfort as a cause for patients' symptoms before initiating treatment. (See
         <a class="medical medical_review" href="/z/d/html/4824.html" rel="external">
          "Diagnosis of delirium and confusional states"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4823.html" rel="external">
          "Delirium and acute confusional states: Prevention, treatment, and prognosis"
         </a>
         .)
        </p>
        <p>
         Patients with FTD are susceptible to adverse effects of medications (such as anxiolytics and antipsychotics) used to treat behavioral symptoms [
         <a href="#rid25">
          25
         </a>
         ]. These adverse effects may include paradoxical behavioral reactions, extrapyramidal side effects, confusion, and sedation. These adverse effects are described in more detail separately (see
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         ). To mitigate these effects, we start with the lowest available dose, titrate the dose upward slowly, and frequently monitor for side effects. In our clinic, we use serotonergic medications as first-line treatments for behavioral symptoms.
        </p>
        <p>
         Because the side effects of various medications may exacerbate behavioral symptoms, slow movement and reaction times, and contribute to confusion, the role of each medication should be continuously reevaluated; medications of unclear benefit should be tapered cautiously.
        </p>
        <p class="headingAnchor" id="H9729311">
         <span class="h3">
          Serotonergic medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         A treatment trial of a serotonin reuptake inhibitor (eg,
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         10 to 20 mg once daily) or
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         25 mg once daily is suggested as initial pharmacotherapy for patients with troubling behavioral symptoms of FTD. Doses can be gradually titrated according to symptomatic improvement or may be limited by side effects, but are generally kept low. The evidence supporting the use of serotonergic medications is stronger than for other classes of medications. However, this evidence comes mostly from uncontrolled observations rather than from controlled clinical trials. In our clinic, we typically allow several weeks after a slow titration to evaluate whether the selective serotonin reuptake inhibitor (SSRI) is providing a benefit before trying a different medication in this class.
        </p>
        <p>
         SSRIs (eg,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         ) have been reported to decrease disinhibition, anxiety, impulsivity, repetitive behaviors, and eating disorders in case reports and small observational studies of patients with FTD [
         <a href="#rid12">
          12,24,26-31
         </a>
         ]. Individual patients with sexual disinhibition have been treated with SSRIs with success [
         <a href="#rid26">
          26,32
         </a>
         ]. In a case series of four patients, pathologic stealing behavior was not attenuated with SSRI therapy [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         An unblinded, randomized trial of 16 patients compared the SSRI
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         (up to 20 mg per day) and piracetam (up to 1200 mg per day). At 14 months, treatment with paroxetine was associated with significant improvement in behavioral symptoms and decreased caregiver stress compared with piracetam-treated patients [
         <a href="#rid27">
          27
         </a>
         ]. By contrast, another double-blinded, randomized crossover trial in 10 patients found that six weeks of paroxetine, rapidly escalated to a dose of 40 mg per day, was not associated with improvements in behavioral or executive function outcomes [
         <a href="#rid34">
          34
         </a>
         ]. An open-label trial of
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         in 15 patients with bvFTD showed improvement of behavioral symptoms over a six-week period [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Low doses of
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         , an atypical serotonergic antidepressant agent, have been reported to be effective in treating agitation and aggression in patients with FTD in observational studies [
         <a href="#rid10">
          10
         </a>
         ]. A double-blinded, randomized crossover trial of trazodone in 26 patients with FTD found a significant reduction in neuropsychiatric symptoms with trazodone as compared with placebo [
         <a href="#rid36">
          36
         </a>
         ]. Benefits of treatment were most notable for irritability, agitation, depressive symptoms, and eating disorders.
        </p>
        <p class="headingAnchor" id="H2129508698">
         <span class="h3">
          Alternative medications
         </span>
        </p>
        <p class="headingAnchor" id="H9729318">
         <span class="h4">
          Antipsychotic medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical antipsychotic medications (eg,
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         ) can help with agitation and other neurobehavioral symptoms in FTD [
         <a href="#rid24">
          24,26,37,38
         </a>
         ]. However, because of adverse effects and increased risk of mortality, antipsychotic medications should be considered a last resort only after trying behavioral modifications and SSRIs. In the United States there is a US Food and Drug Administration (FDA) black box warning for use of all antipsychotics in dementia, due to increased risk of cerebrovascular events and mortality [
         <a href="#rid39">
          39
         </a>
         ]. If multiple trials of SSRIs do not help behavioral symptoms, low-dose quetiapine (eg, 12.5 mg starting dose) may be added and titrated slowly as needed, with careful monitoring for side effects. (See
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Antipsychotic drugs'
         </a>
         .)
        </p>
        <p>
         In one case series, 17 patients with FTD were treated with
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         2.5 to 10 mg per day and followed for 24 months [
         <a href="#rid37">
          37
         </a>
         ]. Treatment was associated with a decrease in delusions and other neurobehavioral symptoms as well as reduced caregiver stress. Somnolence was observed in almost a third, but could be managed by dose reductions.
        </p>
        <p>
         Patients with FTD are particularly vulnerable to the extrapyramidal side effects of antipsychotics. These medications should be used with great caution. Depot preparations, typical antipsychotic agents, and
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         should be avoided [
         <a href="#rid25">
          25,40,41
         </a>
         ].
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          Quetiapine
         </a>
         has moderate D2 receptor antagonism relative to other antipsychotic medications and may cause fewer extrapyramidal side effects [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         Patients and family members should be informed that use of antipsychotic medications has been associated with increased mortality in older adult patients with dementia. (See
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Mortality risk'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9729347">
         <span class="h4">
          Stimulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical evidence supporting the benefit of stimulants is very limited in patients with FTD, and we generally discourage their use. These medications can precipitate delirium in some patients.
        </p>
        <p>
         The rationale for use of stimulants such as
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         is that they may ameliorate dopaminergic deficits present in FTD and thus affect behavioral changes, in particular apathy. Methylphenidate increases synaptic levels of dopamine and norepinephrine.
        </p>
        <p>
         A case report [
         <a href="#rid43">
          43
         </a>
         ] and a small case series [
         <a href="#rid44">
          44
         </a>
         ] reported behavioral improvements in apathy and disinhibition with
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         and
         <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">
          dextroamphetamine
         </a>
         , respectively. A double-blind placebo-controlled crossover study using a single 40 mg dose of methylphenidate in eight FTD patients revealed that treatment was associated with diminished risk-taking behavior as assessed by the Cambridge Gambling Task [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9729376">
         <span class="h4">
          Other agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10131" href="/z/d/drug information/10131.html" rel="external">
          Memantine
         </a>
         is not recommended for use in patients with FTD. Although initial small, open-label studies suggested that memantine improved behavioral symptoms in patients with FTD [
         <a href="#rid24">
          24,46-50
         </a>
         ], two randomized double-blind trials failed to confirm these findings [
         <a href="#rid51">
          51,52
         </a>
         ]. In one trial that included 49 patients with bvFTD randomized to receive either memantine or placebo for one year, there were no differences in clinical endpoints between the two groups [
         <a href="#rid51">
          51
         </a>
         ]. A larger randomized trial also showed no change in neuropsychiatric measures or clinical status, and in fact, patients treated with memantine showed more frequent cognitive adverse events than those taking placebo [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antiseizure medications (eg,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ) have been used to manage neurobehavioral symptoms in other neurodegenerative dementias, but without convincing evidence of efficacy (see
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Drugs with uncertain benefit'
         </a>
         ). One case report documented that
         <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">
          topiramate
         </a>
         was associated with improvement with alcohol use disorder but not other compulsive behaviors [
         <a href="#rid53">
          53
         </a>
         ]. Other reports have noted that valproate therapy has been associated with reduced agitation and self-neglect [
         <a href="#rid26">
          26,54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is sparse evidence for the use of monoamine oxidase (MAO) inhibitors in FTD.
         <a class="drug drug_general" data-topicid="9883" href="/z/d/drug information/9883.html" rel="external">
          Selegiline
         </a>
         improved behavior and attention in three patients with FTD [
         <a href="#rid55">
          55
         </a>
         ]. In another report, six FTD patients taking
         <a class="drug drug_general" data-topicid="10059" href="/z/d/drug information/10059.html" rel="external">
          moclobemide
         </a>
         demonstrated improvements in depression, aggressivity, speech, and stereotyped behavior [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one patient with inappropriate sexual behavior, conjugated estrogen (eg, Premarin) 0.625 mg per day appeared to be helpful [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benzodiazepines are generally not recommended in FTD because they have negative effects on cognition and can precipitate paradoxical agitation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9729426">
         <span class="h2">
          Parkinsonism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with FTD who have parkinsonism typically do not respond to dopaminergic medications such as levodopa or
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         , although some patients have transient motor improvements on these medications [
         <a href="#rid26">
          26
         </a>
         ]. Psychosis and vivid dreaming can be limiting side effects. Patients may receive a treatment trial of levodopa-carbidopa, although response to this medication is often minimal or transient [
         <a href="#rid57">
          57,58
         </a>
         ]. A trial of dopamine agonists can also be considered in those who do not respond to levodopa-carbidopa, although the response can be poor. (See
         <a class="medical medical_review" href="/z/d/html/4896.html" rel="external">
          "Initial pharmacologic treatment of Parkinson disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9729485">
         <span class="h1">
          FUTURE APPROACHES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disease-modifying approaches to the treatment of FTD and related disorders are underway. These experimental drugs include anti-tau antibodies, microtubule stabilizers, drugs to inhibit tau aggregation and acetylation, and drugs targeted toward disease-causing genetic mutations for FTD [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H712260">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         FTD has a younger age of onset and appears to progress more rapidly than Alzheimer disease (AD) [
         <a href="#rid60">
          60-62
         </a>
         ]. Survival from symptom onset is approximately 8 to 10 years and is often shorter in patients with the behavioral variant of FTD (bvFTD) than those with primary progressive aphasia [
         <a href="#rid63">
          63-69
         </a>
         ]. Patients with bvFTD with motor neuron disease have the shortest disease duration of approximately two years [
         <a href="#rid60">
          60,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H712279">
         <span class="h1">
          PALLIATIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the terminal stages of dementia, patients and their caregivers are faced with a range of physical and psychosocial needs, and effective palliative care can improve patients' symptoms, lessen caregiver burden, and help ensure that treatment decisions are well informed and weighed in the context of patient and family goals and needs. Aspects of palliative care that are specific to patients with advanced dementia are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/86250.html" rel="external">
          "Care of patients with advanced dementia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H650490693">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116344.html" rel="external">
          "Society guideline links: Cognitive impairment and dementia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9729492">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment goals and other considerations
         </strong>
         – There are currently no effective disease-modifying treatments for frontotemporal dementia (FTD). Both pharmacologic and nonpharmacologic interventions are aimed at ameliorating symptoms, particularly the behavioral symptoms of FTD.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with FTD are susceptible to adverse effects of medications including paradoxical behavioral reactions, extrapyramidal side effects, confusion, and sedation. Starting with the lowest available dose of medication, slow upward dose titration, and frequent monitoring for side effects are recommended. Medications should be regularly reevaluated. (See
         <a class="local">
          'Considerations prior to treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonpharmacologic interventions
         </strong>
         – These are an important facet of the management of patients with FTD and can include an exercise program; modification of the home environment; increased supervision; physical, occupational, and speech therapy; behavioral modification techniques; and caregiver support and respite. (See
         <a class="local">
          'Nonpharmacologic interventions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited role for cholinesterase inhibitors
         </strong>
         – Cholinesterase inhibitors do not have convincing evidence of benefit in patients with FTD and do not have a role in symptomatic management, unless there is diagnostic uncertainty, and a diagnosis of Alzheimer disease (AD) seems equally as likely as FTD. (See
         <a class="local">
          'Cognitive dysfunction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5072.html" rel="external">
          "Cholinesterase inhibitors in the treatment of dementia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurobehavioral problems
         </strong>
         – When neurobehavioral problems appear or worsen, clinicians should consider the possibility of delirium, pain, or discomfort as a cause for these symptoms before initiating pharmacologic treatment. (See
         <a class="local">
          'Considerations prior to treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with troubling neurobehavioral symptoms of FTD despite nonpharmacologic interventions, we suggest a treatment trial of a serotonin reuptake inhibitor (eg,
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         10 to 20 mg once daily) or
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         25 mg once daily (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Serotonergic medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other treatment options include atypical antipsychotic agents to be used as a last resort. Patients with FTD need to be carefully monitored for extrapyramidal side effects, for which they are particularly vulnerable. If needed, we use a low dose of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         (eg, 12.5 to 25 mg), which has fewer reported extrapyramidal side effects relative to other antipsychotic medications. The US Food and Drug Administration (FDA) has issued a black box warning for all antipsychotics in dementia due to increased risk of adverse events and mortality, and families should be warned about these risks with use of these medications in this setting. (See
         <a class="local">
          'Antipsychotic medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3065428689">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Bruce L Miller, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. J Neurol Neurosurg Psychiatry 1994; 57:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry RJ, Miller BL. Behavior and treatment in frontotemporal dementia. Neurology 2001; 56:S46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrilees JJ, Miller BL. Long-term care of patients with frontotemporal dementia. J Am Med Dir Assoc 2003; 4:S162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011; 10:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson KM. Rehabilitation applications in caring for patients with Pick's disease and frontotemporal dementias. Neurology 2001; 56:S56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talerico KA, Evans LK. Responding to safety issues in frontotemporal dementias. Neurology 2001; 56:S52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2007; 21:S64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bei Hu, Ross L, Neuhaus J, et al. Off-label medication use in frontotemporal dementia. Am J Alzheimers Dis Other Demen 2010; 25:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006; 66:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis PT, Holmes C, Webster MT, et al. Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy. Dementia 1993; 4:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanctôt KL, Herrmann N, Ganjavi H, et al. Serotonin-1A receptors in frontotemporal dementia compared with controls. Psychiatry Res 2007; 156:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999; 10 Suppl 1:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol 1991; 48:796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rinne JO, Laine M, Kaasinen V, et al. Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia. Neurology 2002; 58:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frisoni GB, Pizzolato G, Bianchetti A, et al. Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results. Acta Neurol Scand 1994; 89:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engelborghs S, Vloeberghs E, Le Bastard N, et al. The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia. Neurochem Int 2008; 52:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord 2008; 25:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging 2004; 21:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry 2007; 15:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int 2013; 13:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arciniegas DB, Anderson CA. Donepezil-induced confusional state in a patient with autopsy-proven behavioral-variant frontotemporal dementia. J Neuropsychiatry Clin Neurosci 2013; 25:E25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendez MF. Frontotemporal dementia: therapeutic interventions. Front Neurol Neurosci 2009; 24:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pijnenburg YA, Sampson EL, Harvey RJ, et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry 2003; 18:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2002; 17:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003; 49:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord 2005; 20:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement Geriatr Cogn Disord 2004; 17:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manes FF, Torralva T, Roca M, et al. Frontotemporal dementia presenting as pathological gambling. Nat Rev Neurol 2010; 6:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson IM, Scott K, Harborne G. Serotonin and depression in frontal lobe dementia. Am J Psychiatry 1995; 152:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 2007; 8:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendez MF. Pathological stealing in dementia: poor response to SSRI medications. J Clin Psychiatry 2011; 72:418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology (Berl) 2004; 172:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herrmann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatry 2012; 20:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 2003; 18:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fellgiebel A, Müller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 2007; 8:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry 2012; 169:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerssens CJ, Pijnenburg YA. Vulnerability to neuroleptic side effects in frontotemporal dementia. Eur J Neurol 2008; 15:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czarnecki K, Kumar N, Josephs KA. Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics? Eur J Neurol 2008; 15:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Komossa K, Rummel-Kluge C, Schmid F, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; :CD006625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goforth HW, Konopka L, Primeau M, et al. Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study. Clin EEG Neurosci 2004; 35:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huey ED, Garcia C, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry 2008; 69:1981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology 2006; 31:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vossel KA, Miller BL. New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol 2008; 21:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord 2007; 21:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diehl-Schmid J, Förstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry 2008; 23:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow TW, Graff-Guerrero A, Verhoeff NP, et al. Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat 2011; 7:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 2009; 23:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vercelletto M, Boutoleau-Bretonnière C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis 2011; 23:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2013; 12:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz M, Marinho V, Fontenelle LF, et al. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol 2008; 21:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gálvez-Andres A, Blasco-Fontecilla H, González-Parra S, et al. Secondary bipolar disorder and Diogenes syndrome in frontotemporal dementia: behavioral improvement with quetiapine and sodium valproate. J Clin Psychopharmacol 2007; 27:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moretti R, Torre P, Antonello RM, et al. Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation. Int J Geriatr Psychiatry 2002; 17:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adler G, Teufel M, Drach LM. Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide. Int J Geriatr Psychiatry 2003; 18:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litvan I, Grimes DA, Lang AE, et al. Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration. J Neurol 1999; 246 Suppl 2:II1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Balken I, Litvan I. Current and future treatments in progressive supranuclear palsy. Curr Treat Options Neurol 2006; 8:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem 2016; 138 Suppl 1:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberson ED, Hesse JH, Rose KD, et al. Frontotemporal dementia progresses to death faster than Alzheimer disease. Neurology 2005; 65:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binetti G, Locascio JJ, Corkin S, et al. Differences between Pick disease and Alzheimer disease in clinical appearance and rate of cognitive decline. Arch Neurol 2000; 57:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rascovsky K, Salmon DP, Lipton AM, et al. Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 2005; 65:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosso SM, Donker Kaat L, Baks T, et al. Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 2003; 126:2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodges JR, Davies R, Xuereb J, et al. Survival in frontotemporal dementia. Neurology 2003; 61:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knibb JA, Xuereb JH, Patterson K, Hodges JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol 2006; 59:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Ber I, Guedj E, Gabelle A, et al. Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain 2006; 129:3051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neary D, Snowden J, Mann D. Frontotemporal dementia. Lancet Neurol 2005; 4:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcin B, Lillo P, Hornberger M, et al. Determinants of survival in behavioral variant frontotemporal dementia. Neurology 2009; 73:1656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 2016; 86:1736.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14139 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8163988" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11402151" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Behavior and treatment in frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14613593" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Long-term care of patients with frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21147039" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385882" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11402153" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Rehabilitation applications in caring for patients with Pick's disease and frontotemporal dementias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11402152" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Responding to safety issues in frontotemporal dementias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18090427" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A model for management of behavioral symptoms in frontotemporal lobar degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20124256" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Off-label medication use in frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16401839" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8401788" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Preliminary neurochemical findings in non-Alzheimer dementia due to lobar atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9184615" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17976961" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Serotonin-1A receptors in frontotemporal dementia compared with controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10436347" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Neurochemical features of frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1898253" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Altered serotonergic and cholinergic synaptic markers in Pick's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12034784" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Striatal dopamine transporter and extrapyramidal symptoms in frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8030401" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Single photon emission computed tomography with [99Tc]-HM-PAO and [123I]-IBZM in Alzheimer's disease and dementia of frontal type: preliminary results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18093695" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The dopaminergic neurotransmitter system is associated with aggression and agitation in frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18196898" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Galantamine in frontotemporal dementia and primary progressive aphasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15554751" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Rivastigmine in frontotemporal dementia: an open-label study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17194818" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23551349" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24026732" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Donepezil-induced confusional state in a patient with autopsy-proven behavioral-variant frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19182475" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Frontotemporal dementia: therapeutic interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12497558" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12392261" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12464713" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15786492" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Stereotypical movements and frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14739531" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20440289" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Frontotemporal dementia presenting as pathological gambling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7694920" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Serotonin and depression in frontal lobe dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17538783" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21450164" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pathological stealing in dementia: poor response to SSRI medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14666399" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21878805" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15178953" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Frontotemporal dementia: a randomised, controlled trial with trazodone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12955785" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17455105" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22952071" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Atypical antipsychotic use in patients with dementia: managing safety concerns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18217880" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Vulnerability to neuroleptic side effects in frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18217890" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20091600" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Quetiapine versus other atypical antipsychotics for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15164821" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: a case study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19203481" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Stimulant treatment of frontotemporal dementia in 8 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16160709" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18989117" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : New approaches to the treatment of frontotemporal lobar degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17545743" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Memantine for behavioral disturbances in frontotemporal dementia: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18213609" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A 6-month, open-label study of memantine in patients with frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21792308" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19812461" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21157021" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Memantine in behavioral variant frontotemporal dementia: negative results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23290598" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18541987" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18004150" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Secondary bipolar disorder and Diogenes syndrome in frontotemporal dementia: behavioral improvement with quetiapine and sodium valproate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11994896" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Effects of selegiline on fronto-temporal dementia: a neuropsychological evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12833310" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10525996" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical features differentiating patients with postmortem confirmed progressive supranuclear palsy and corticobasal degeneration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16569380" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Current and future treatments in progressive supranuclear palsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27306957" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Therapy and clinical trials in frontotemporal dementia: past, present, and future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16157905" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Frontotemporal dementia progresses to death faster than Alzheimer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10681082" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Differences between Pick disease and Alzheimer disease in clinical appearance and rate of cognitive decline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16087904" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Rate of progression differs in frontotemporal dementia and Alzheimer disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12876142" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12913196" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Survival in frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16374817" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Clinical and pathological characterization of progressive aphasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17071924" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16239184" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19917988" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Determinants of survival in behavioral variant frontotemporal dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27037234" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
